EyePoint Sues Ocular Therapeutix Over Eye Drug Claims

Lawsuit Overview

EyePoint Pharmaceuticals has filed a lawsuit against its competitor, Ocular Therapeutix, in Massachusetts Superior Court. The complaint accuses Ocular of disseminating false and misleading information concerning EyePoint and its primary experimental drug, Duravyu.

The allegations include defamation, commercial disparagement, and violations of Massachusetts consumer protection laws. EyePoint asserts that Ocular's statements have interfered with its business relationships.

Market Competition Context

Both companies are significant players in the development of long-lasting treatments for severe retinal diseases, including wet age-related macular degeneration or wet AMD. This condition is a leading cause of vision loss among older adults.

EyePoint's Duravyu is currently in late-stage trials, with key data anticipated by mid-2026. Meanwhile, Ocular’s drug, Axpaxli, successfully met its main goal in a recent late-stage trial for wet AMD.

Legal and Market Implications

EyePoint is seeking a court order to halt the alleged false statements, demanding a public retraction and compensation for monetary damages and legal fees. In response, a spokesperson for Ocular Therapeutix stated the company is confident in its statements and prepared to address the matter through the legal process.

The lawsuit highlights the intense competition in the ophthalmic drug market, where clinical data and corporate reputation are critical for success.

Summary

This legal conflict between EyePoint and Ocular Therapeutix underscores the high stakes in the race to market new treatments for retinal diseases. The outcome could significantly impact both companies' standing and the perception of their drug candidates. Investors will be closely watching the proceedings for further developments.

FAQ

Q: What are the main allegations in the lawsuit?
A: EyePoint alleges defamation, commercial disparagement, and violations of consumer protection law by Ocular Therapeutix regarding its drug Duravyu.

Q: Which drugs are at the center of this rivalry?
A: The rivalry involves EyePoint's experimental drug Duravyu and Ocular Therapeutix's leading drug Axpaxli, both targeting wet AMD.

Source: Reuters via Investing.com